No Data
No Data
Hainan Poly Pharm Gets Nod to Trial Tumor Drug
Does The Market Have A Low Tolerance For Hainan Poly Pharm. Co., Ltd's (SZSE:300630) Mixed Fundamentals?
Annual report "difficult birth"! Hakuba pharmaceutical stocks receive fines and are once again put on file, with a 20% plummet upon resumption of trading!
The company has been investigated by the China Securities Regulatory Commission for the second time this year.
Hainan Poly Pharm (300630.SZ): Currently under investigation by the China Securities Regulatory Commission.
Hainan Poly Pharm (300630.SZ) announced that the company has received a Notice of Filing from the China Securities Regulatory Commission (CSRC) due to suspected violation of securities laws and regulations.
Hainan Poly Pharm: First-quarter report of 2024.
Hainan Poly Pharm: 2023 Annual Report
No Data